<?xml version='1.0' encoding='utf-8'?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2011//EN" "http://www.ncbi.nlm.nih.gov/entrez/query/DTD/pubmed_110101.dtd">
<pubmedarticleset>
 <pubmedarticle>
  <medlinecitation owner="NLM" status="MEDLINE">
   <pmid version="1">
    16102557
   </pmid>
   <datecreated>
    <year>
     2005
    </year>
    <month>
     08
    </month>
    <day>
     16
    </day>
   </datecreated>
   <datecompleted>
    <year>
     2006
    </year>
    <month>
     01
    </month>
    <day>
     06
    </day>
   </datecompleted>
   <daterevised>
    <year>
     2007
    </year>
    <month>
     11
    </month>
    <day>
     15
    </day>
   </daterevised>
   <article pubmodel="Print">
    <journal>
     <issn issntype="Print">
      0010-7824
     </issn>
     <journalissue citedmedium="Print">
      <volume>
       72
      </volume>
      <issue>
       3
      </issue>
      <pubdate>
       <year>
        2005
       </year>
       <month>
        Sep
       </month>
      </pubdate>
     </journalissue>
     <title>
      Contraception
     </title>
     <isoabbreviation>
      Contraception
     </isoabbreviation>
    </journal>
    <articletitle>
     Effects of an oral contraceptive (norgestimate/ethinyl estradiol) on bone mineral density in women with hypothalamic amenorrhea and osteopenia: an open-label extension of a double-blind, placebo-controlled study.
    </articletitle>
    <pagination>
     <medlinepgn>
      206-11
     </medlinepgn>
    </pagination>
    <abstract>
     <abstracttext label="OBJECTIVE" nlmcategory="OBJECTIVE">
      The effects of long-term triphasic oral contraceptive administration on bone mineral density (BMD) were investigated in premenopausal women with hypothalamic amenorrhea (HA) and osteopenia.
     </abstracttext>
     <abstracttext label="METHODS" nlmcategory="METHODS">
      After completing three 28-day cycles in the double-blind phase of a placebo-controlled trial, women (mean age, 26.7 years) who received norgestimate 180-250 microg/ethinyl estradiol 35 microg (NGM/EE, n = 15) or placebo (n = 12) in the double-blind phase were to receive open-label NGM/EE for 10 additional cycles.
     </abstracttext>
     <abstracttext label="RESULTS" nlmcategory="RESULTS">
      For subjects completing &gt; or =10 NGM/EE treatment cycles, mean posteroanterior total lumbar spine BMD (L1-L4) increased from 0.881+/-0.0624 g/cm2 at baseline (last visit prior to NGM/EE) to 0.894+/-0.0654 g/cm2 at final visit (p = .043); no significant changes in hip BMD occurred. Decreases in N-telopeptide, osteocalcin, procollagen type I propeptide and bone-specific alkaline phosphatase levels indicated effects on bone metabolism.
     </abstracttext>
     <abstracttext label="CONCLUSIONS" nlmcategory="CONCLUSIONS">
      Long-term administration of triphasic NGM/EE to osteopenic women with HA may increase total lumbar spine BMD.
     </abstracttext>
    </abstract>
    <affiliation>
     Columbia University, College of Physicians and Surgeons, Department of Obstetrics and Gynecology, PH 16-128, New York, NY 10032, USA. mpw1@columbia.edu
    </affiliation>
    <authorlist completeyn="Y">
     <author validyn="Y">
      <lastname>
       Warren
      </lastname>
      <forename>
       Michelle P
      </forename>
      <initials>
       MP
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Miller
      </lastname>
      <forename>
       K K
      </forename>
      <initials>
       KK
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Olson
      </lastname>
      <forename>
       W H
      </forename>
      <initials>
       WH
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Grinspoon
      </lastname>
      <forename>
       S K
      </forename>
      <initials>
       SK
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Friedman
      </lastname>
      <forename>
       A J
      </forename>
      <initials>
       AJ
      </initials>
     </author>
    </authorlist>
    <language>
     eng
    </language>
    <publicationtypelist>
     <publicationtype>
      Journal Article
     </publicationtype>
     <publicationtype>
      Randomized Controlled Trial
     </publicationtype>
    </publicationtypelist>
   </article>
   <medlinejournalinfo>
    <country>
     United States
    </country>
    <medlineta>
     Contraception
    </medlineta>
    <nlmuniqueid>
     0234361
    </nlmuniqueid>
    <issnlinking>
     0010-7824
    </issnlinking>
   </medlinejournalinfo>
   <chemicallist>
    <chemical>
     <registrynumber>
      0
     </registrynumber>
     <nameofsubstance>
      Biological Markers
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      0
     </registrynumber>
     <nameofsubstance>
      Contraceptives, Oral, Synthetic
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      35189-28-7
     </registrynumber>
     <nameofsubstance>
      norgestimate
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      57-63-6
     </registrynumber>
     <nameofsubstance>
      Ethinyl Estradiol
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      6533-00-2
     </registrynumber>
     <nameofsubstance>
      Norgestrel
     </nameofsubstance>
    </chemical>
   </chemicallist>
   <citationsubset>
    IM
   </citationsubset>
   <meshheadinglist>
    <meshheading>
     <descriptorname majortopicyn="N">
      Absorptiometry, Photon
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Adolescent
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Adult
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Amenorrhea
     </descriptorname>
     <qualifiername majortopicyn="N">
      complications
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Biological Markers
     </descriptorname>
     <qualifiername majortopicyn="N">
      metabolism
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Bone Density
     </descriptorname>
     <qualifiername majortopicyn="Y">
      drug effects
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Bone Diseases, Metabolic
     </descriptorname>
     <qualifiername majortopicyn="N">
      complications
     </qualifiername>
     <qualifiername majortopicyn="N">
      metabolism
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Contraceptives, Oral, Synthetic
     </descriptorname>
     <qualifiername majortopicyn="N">
      administration &amp; dosage
     </qualifiername>
     <qualifiername majortopicyn="Y">
      pharmacology
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Double-Blind Method
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Ethinyl Estradiol
     </descriptorname>
     <qualifiername majortopicyn="N">
      administration &amp; dosage
     </qualifiername>
     <qualifiername majortopicyn="Y">
      pharmacology
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Female
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Humans
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Hypothalamic Diseases
     </descriptorname>
     <qualifiername majortopicyn="N">
      complications
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Lumbar Vertebrae
     </descriptorname>
     <qualifiername majortopicyn="N">
      radiography
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Norgestrel
     </descriptorname>
     <qualifiername majortopicyn="N">
      administration &amp; dosage
     </qualifiername>
     <qualifiername majortopicyn="Y">
      analogs &amp; derivatives
     </qualifiername>
     <qualifiername majortopicyn="N">
      pharmacology
     </qualifiername>
    </meshheading>
   </meshheadinglist>
  </medlinecitation>
  <pubmeddata>
   <history>
    <pubmedpubdate pubstatus="received">
     <year>
      2004
     </year>
     <month>
      12
     </month>
     <day>
      22
     </day>
    </pubmedpubdate>
    <pubmedpubdate pubstatus="revised">
     <year>
      2005
     </year>
     <month>
      3
     </month>
     <day>
      18
     </day>
    </pubmedpubdate>
    <pubmedpubdate pubstatus="accepted">
     <year>
      2005
     </year>
     <month>
      3
     </month>
     <day>
      26
     </day>
    </pubmedpubdate>
    <pubmedpubdate pubstatus="pubmed">
     <year>
      2005
     </year>
     <month>
      8
     </month>
     <day>
      17
     </day>
     <hour>
      9
     </hour>
     <minute>
      0
     </minute>
    </pubmedpubdate>
    <pubmedpubdate pubstatus="medline">
     <year>
      2006
     </year>
     <month>
      1
     </month>
     <day>
      7
     </day>
     <hour>
      9
     </hour>
     <minute>
      0
     </minute>
    </pubmedpubdate>
    <pubmedpubdate pubstatus="entrez">
     <year>
      2005
     </year>
     <month>
      8
     </month>
     <day>
      17
     </day>
     <hour>
      9
     </hour>
     <minute>
      0
     </minute>
    </pubmedpubdate>
   </history>
   <publicationstatus>
    ppublish
   </publicationstatus>
   <articleidlist>
    <articleid idtype="pii">
     S0010-7824(05)00100-9
    </articleid>
    <articleid idtype="doi">
     10.1016/j.contraception.2005.03.007
    </articleid>
    <articleid idtype="pubmed">
     16102557
    </articleid>
   </articleidlist>
  </pubmeddata>
 </pubmedarticle>
</pubmedarticleset>

